Paracetamol orodispersible tablets: a risk for severe poisoning in children?

Ceschi, A; Hofer, K E; Rauber-Lüthy, C; Kupferschmidt, H

Abstract: PURPOSE: Childhood paracetamol (acetaminophen) ingestion with subsequent risk of hepatotoxicity is a major medical problem. The aim of this study was to investigate the risk of high-dose ingestion of orodispersible, fast-dissolving paracetamol tablets in children. METHODS: A retrospective single-center case study of all accidental selfadministrations of solid or orodispersible 500-mg paracetamol tablets occurring in children ≤ 6 years, reported to the Swiss Toxicological Information Centre between June 2003 and August 2009. RESULTS: We found 187 cases with ingestion of solid 500-mg paracetamol tablets and 16 cases with ingestion of orodispersible 500-mg tablets. The mean ingested dose in the orodispersible-tablet group was 59% higher than in the solid-tablet group (p = 0.085). Administration of activated charcoal and/or N-acetylcysteine because of ingestion of a potentially hepatotoxic paracetamol dose (≥ 150 mg/kg body weight) was recommended in 32 patients (17.1%) in the solid-tablet group and in five (31%) in the orodispersible-tablet group. CONCLUSIONS: Orodispersible paracetamol formulations may represent an important risk factor for severe paracetamol poisoning in children. Over-the-counter availability may contribute to increasing the use of this galenic formulation and eventually the number of poisonings in children.

DOI: https://doi.org/10.1007/s00228-010-0943-x

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-60346
Accepted Version

Originally published at:
DOI: https://doi.org/10.1007/s00228-010-0943-x
Paracetamol Orodispersible Tablets: A Risk for Severe Poisoning in Children?

Alessandro Ceschi\textsuperscript{1}, Katharina E Hofer\textsuperscript{1}, Christine Rauber-Lüthy\textsuperscript{1}, Hugo Kupferschmidt\textsuperscript{1}

\textsuperscript{1}Swiss Toxicological Information Centre, Zurich, Switzerland

**Corresponding author:**

Alessandro Ceschi, MD
Swiss Toxicological Information Centre
Division of Science
Freiestrasse 16
CH-8032 Zurich
Tel: +41-44-634-1034
Fax: +41-44-252-8833
e-mail: Alessandro.Ceschi@usz.ch

**Keywords:** Paracetamol, Acetaminophen, Poisoning, Toxicity, Children.

**Word count** (without table and references): 792.
Introduction
Childhood paracetamol (acetaminophen) ingestion with the inherent risk of hepatotoxicity is a major medical problem in most parts of the world. The issue of over-the-counter medications leading to unintentional ingestions in children and the importance of child-resistant closures for liquid paracetamol preparations has already been addressed in previous studies [1, 2]. At the beginning of 2002, an over-the-counter orodispersible paracetamol formulation was licensed in Switzerland. The aim of the present study was to investigate the risk of high-dose ingestion of orodispersible fast disintegrating paracetamol tablets in children.

Methods
Data acquisition and Inclusion criteria
The Swiss Toxicological Information Centre (STIC) collects specific informations from laypersons and detailed clinical reports from physicians and hospitals about poisoning cases, by means of an in-house computer-based and structured data-recording and analysis system [3]. At the time of the initial phone call clinical information is obtained such as age and gender of the patient, circumstances of intoxication, ingested doses of all substances involved, symptoms and causality. These data are verified and supplemented by information from discharge letters and laboratory reports where available. We performed a retrospective single-centre analysis of all cases reported to our centre of accidental self-administration of solid or orodispersible 500 mg paracetamol tablets occurring in children up to 6 years during the period June 2003 - August 2009. Only cases with acute ingestion of a single substance (paracetamol) and available information on the ingested dose were included.

Statistical evaluation
Statistical analysis was performed with SPSS software (Version 17.0; SPSS Inc., Chicago, IL, USA). Between-group comparisons were made using the Mann-Whitney U-test (2-tailed).

Results
A search of our database yielded 187 pediatric cases with ingestion of solid 500 mg paracetamol tablets (group 1) and 16 pediatric cases with ingestion of orodispersible
500 mg tablets (group 2) which were fulfilling the inclusion criteria. A comparison of the two groups in terms of age of the patients, number of ingested tablets and ingested dose is shown in table 1. The mean ingested dose in the orodispersible tablet group was 59% higher than in the solid tablet group, although the difference did not reach statistical significance (p=0.085). In 9 patients (4.8%) in the solid tablet group and 1 patient (6.25%) in the orodispersible tablet group, primary gastrointestinal decontamination with oral activated charcoal was recommended because paracetamol intake was between 150 and 200 mg/kg body weight. In 23 patients (12.3%) in the solid tablet group and 4 patients (25%) in the orodispersible tablet group, hospitalization for N-acetylcysteine (NAC) treatment was recommended because paracetamol intake was ≥200 mg/kg body weight. Overall, administration of oral activated charcoal and/or NAC because of ingestion of a potentially hepatotoxic paracetamol dose, was recommended in 32 patients (7.1%) in the solid tablet group and in 5 patients (31%) in the orodispersible tablet group.

The analysis of the clinical course of paracetamol-poisoned children was not the focus of this study. However, among the cases where such information was available, no symptoms or signs of hepatotoxicity were observed and patients remained asymptomatic, except for two patients among those hospitalized for NAC administration, who showed mild gastrointestinal symptoms such as nausea and vomiting (one in the orodispersible tablet group and one in the solid tablet group).

**Discussion**

Possible factors leading to ingestion of higher paracetamol doses with the orodispersible formulations are the rapid disintegration of the tablets within seconds of contact with saliva, the pleasant feeling in the mouth, the masked bitter paracetamol taste and the candy-like aspect which may encourage consumption by children [4]. Further factors not directly associated with the orodispersible formulation, as lack of child-resistant closure and blister safety packaging, lack of vigilance by parents and caregivers in the storage of medications and availability of adult-strength tablets may have acted as confounders which we were unable to control for in analyses, and possibly contributed to increasing the risk of high-dose paracetamol ingestion in the orodispersible formulation group.
Study limitations
The interpretation of our findings is limited by the retrospective nature of the study design. In addition, data from poison control centres are subject to reporting bias, as we do not know the percentage of cases reported to the STIC. Furthermore, the decision to only include patients who ingested paracetamol alone, led to small case numbers.

Conclusions
This study highlighted the problem of the availability of orodispersible paracetamol formulations, which may represent an important risk factor for severe paracetamol poisoning in children. Over-the-counter availability may contribute to increasing the use of this galenic formulation and eventually the number of poisonings in children. Further studies with larger case numbers are required to confirm our findings.

Declaration of interest
The authors declare that they have no conflict of interest.
The present work was supported entirely by the internal resources of the Swiss Toxicological Information Centre.

Acknowledgements
None.
References
**Table 1.**
Comparison of cases with solid versus orodispersible paracetamol tablets ingestion

<table>
<thead>
<tr>
<th></th>
<th>Solid paracetamol n = 187</th>
<th>Orodispersible paracetamol n = 16</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years) (range)</strong></td>
<td>mean ± SD 2.3 ± 0.92 (0.8-6)</td>
<td>3 ± 1.21 (1.5-5)</td>
<td>0.046</td>
</tr>
<tr>
<td><strong>Number of ingested tablets (range)</strong></td>
<td>mean ± SD 2.5 ± 1.96 (0.3-8)</td>
<td>4.6 ± 3.76 (1-14)</td>
<td>0.057</td>
</tr>
<tr>
<td><strong>Ingested dose in mg/kg (range)</strong></td>
<td>mean ± SD 98.7 ± 77.7 (8.3-444)</td>
<td>157.3 ± 147.6 (29.4-538)</td>
<td>0.085</td>
</tr>
</tbody>
</table>